


Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/588,323
				Filing/371(c) Date	February 16, 2007
				First Named Inventor	MAGILAVY
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	253780

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
	A 3 5	US-2003/0068320		DINGIVAN	04/10/2003	
OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation			
			Yes	No**		
	C 6 0 8	UNITED STATES PATENT AND TRADEMARK OFFICE, Official Communication relative to Application No. 10/484,329 mailed January 11, 2008 (References cited on form PTO-892 are listed below)				
	C 6 0 9	SELMAN et al., Ann Intern Med. 2001 Jan 16;134(2):136-51				
	C 6 1 0	TROUGHTON et al., Baillieres Clin Rheumatol. 1994 May; 8(2):439-63				
	C 6 1 1	BALL et al., Angew Chem Int Ed Engl. 2005 May 3; 44(19):2852-2869				
	C 6 1 2	ZIWEI HUANG, Pharmacol Ther. 200 Jun; 86(3):201-15				
	C 6 1 3	THE MERRIAM-WEBSTER ONLINE, http://www.m-w.com/cgi-bin/dictionary?interstitial as accessed on December 27, 2007, 1 page. Mavilian et al., Am J. Pathol. 1997 Dec; 151(6):1751-8				
	C 6 1 4	THE MERCK MANUAL OF DIAGNOSIS AND THERAPY, Beers et al, eds., published by Merck Research Laboratories, 17 th ed., 1999, pp. 431-433				
	C 6 1 5	MAYES et al., Environ Health Perspect. 1999 Oct; 107 Suppl 5:743-8				
	C 6 1 6	MAVILIA et al., Am J Pathol. 1997 Dec; 151(6): 1751-8				

Examiner Signature	/Phillip Gambel/	Date Considered	09/30/2008
--------------------	------------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).